Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record.

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Eton, O, Legha, S S, Moon, T E, Buzaid, A C, Papadopoulos, N E, Plager, C, Burgess, A M, Bedikian, A Y, Ring, S, Dong, Q, Glassman, A B, Balch, C M, Benjamin, R S·1998·Journal of Clinical Oncology

Abstract

PURPOSE: The current American Joint Commission on Cancer (AJCC) staging system distinguishes between soft tissue and visceral metastases in advanced (stage IV) melanoma. We sought to verify these staging criteria and to identify prognostic variables that could be used to evaluate the impact of systemic therapy on long-term survival during the prior decade. PATIENTS AND METHODS: We conducted a retrospective study of patients with advanced cutaneous melanoma enrolled in clinical trials between 1979 and 1989 at The University of Texas M.D. Anderson Cancer Center. Pretreatment age, sex, number of organs with metastases, serum levels of lactate dehydrogenase (LDH) and albumin, and period of enrollment were analyzed using a Cox proportional hazards model of survival. RESULTS: In univariate and multivariate analyses that involved 318 stage IV patients, normal serum levels of LDH and albumin, soft tissue and/or single visceral organ metastases (especially lung), female sex, and enrollment late in the decade were independent positive predictors for survival. In multivariate analyses, the current AJCC criteria did not significantly predict outcome. Systemic treatment response did not bias these results, and only 4% of patients had a complete response. Patients who lived more than 2 years (11%) had a mix of favorable prognostic characteristics and a high frequency of systemic or surgically induced complete response. CONCLUSION: This study supports the use of stratification parameters that reflect the favorable prognostic impact of soft tissue or single visceral organ metastases and normal serum levels of LDH and albumin at time of enrollment in advanced melanoma trials. Improved survival over the prior decade probably reflects advances in diagnostic and palliative interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.3.1103

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 218

Metadata

Authors
Eton, O., Legha, S. S., Moon, T. E., Buzaid, A. C., Papadopoulos, N. E., Plager, C., Burgess, A. M., Bedikian, A. Y., Ring, S., Dong, Q., Glassman, A. B., Balch, C. M., & Benjamin, R. S.
Venue
Journal of Clinical Oncology
Published
1998-03
Volume
16
Issue
3
Pages
1103-1111
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2168992823
Cited by
218
References
0
FWCI
3.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic factors for survival of patients treated systemically for disseminated melanoma. https://app.cochat.ai/papers/10.1200/jco.1998.16.3.1103
The paper
Eton, O., Legha, S. S., Moon, T. E., Buzaid, A. C., Papadopoulos, N. E., Plager, C., Burgess, A. M., Bedikian, A. Y., Ring, S., Dong, Q., Glassman, A. B., Balch, C. M., & Benjamin, R. S. (1998). Prognostic factors for survival of patients treated systemically for disseminated melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.3.1103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.